Teva goes to war with Eli Lilly over migraine breakthrough

Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Americas

Teva sues Eli Lilly again after FDA approves migraine drug

1 October 2018 Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

More on this story

Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Americas

Teva sues Eli Lilly again after FDA approves migraine drug

1 October 2018 Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

More on this story

Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Americas

Teva sues Eli Lilly again after FDA approves migraine drug

1 October 2018 Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.